Members

Blog Posts

How to Download CDS 2 2024 GK Answer Key

Posted by Trishul Defence Academy on August 27, 2024 at 7:16am 0 Comments

The Combined Defence Services (CDS) Examination is a competitive exam conducted by the Union Public Service Commission (UPSC) in India. It is held twice a year, usually referred to as CDS 1 and CDS 2, and is a gateway for candidates to join the Indian Military Academy (IMA), Officers Training Academy (OTA), Indian Naval Academy (INA), and Indian Air Force Academy (AFA).

To download the CDS 2 2024 GK…

Continue

Breast Cancer Liquid Biopsy Market Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology)

Breast Cancer Liquid Biopsy Market is the first-class market research report that conducts industry analysis on products, markets, companies, industries and many countries worldwide. The report analyses market information related to specific stock, currency, commodity and geographic region or country. This report deals with numerous parameters in detail to suit the requirements of business or clients. These parameters range from latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights to innovation. All of these are estimated and analyzed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the Breast Cancer Liquid Biopsy Market analysis report.

Get FLAT 25% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1598296

Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.

Some of the major market players in the breast cancer liquid biopsy market are

QIAGEN N.V. (Netherlands),

Roche Diagnostics (US),

Bio-Rad Laboratories (US),

Myriad Genetics (US),

Menarini Silicon Biosystems (Italy),

Illumina (US),

Cynvenio Biosystems, Inc. (US),

Genomic Health, Inc. (US),

Thermo Fisher Scientific Inc. (US),

Fluxion Biosciences, Inc. (US),

Biodesix, Inc. (US),

Guardant Health, Inc. (US),

and Isogen Life Science B.V. (Netherlands).

“Cell-free DNA to register the highest CAGR during the forecast period”

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.

“Reference laboratories to register the largest share during the forecast period”

Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.

“Asia Pacific to witness the highest growth during the forecast period (2017–2022)”

North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.

Break of primary participants was as mentioned below:

By Company Type – Tier 1– 15%, Tier 2– 45%, and Tier 3–40%
By Designation – C-level– 27%, Director Level–33%, Others–40%
By Region – North America–25%, Europe–45%, Asia-Pacific–15%, RoW–15%
Research Coverage:

The report analyzes the breast cancer liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by circulating biomarker, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
Innovation: Detailed insights on upcoming trends and product launches in the global breast cancer liquid biopsy market
Market Development: Comprehensive information on the lucrative emerging markets by product, circulating biomarkers, end user, and region
Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global breast cancer liquid biopsy market
Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy products of leading players in the global market
Enquire Here for, Report Enquiry, Discount and Customization @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name...

Table of Contents

1 Breast Cancer Liquid Biopsy: Market at A Glance
1.1 Introduction
1.2 Issues Addressed By Breast Cancer Liquid Biopsy & Biomarkers Detected
1.3 Milestones in Breast Cancer Liquid Biopsy

2 Breast Cancer Liquid Biopsy: Circulating Biomarkers
2.1 Breast Cancer Liquid Biopsy Market for Circulating Tumor DNA (CTDNA)
2.2 CTDNA Approaches: Applications and Limitations
2.3 Breast Cancer Liquid Biopsy Market By Circulating Tumor DNA (CTDNA)
2.4 Methods for CTC Isolation

3 Breast Cancer Liquid Biopsy: Market Overview
3.1 Introduction
3.1.1 Drivers
3.1.2.1 High Burden of Cancer
3.1.2.2 Increasing Preference for Noninvasive Procedures
3.1.2.3 Initiatives Undertaken By Governments and Global Health Organizations
3.1.2.4 Technological Advancements
3.1.2.5 Rising Emphasis on Personalized Medicine
3.1.2.6 Availability of Funding for Breast Cancer Liquid Biopsy R&D
3.1.2 Restraints
3.1.2.1 Low Sensitivity and Specificity
3.1.3 Opportunities
3.1.3.1 Growing Interest in Breast Cancer Liquid Biopsy
3.1.4 Challenges
3.1.4.1 Unclear Regulatory and Reimbursement Scenario

4 Major Investments & Initiatives
4.1 Government Funding & Initiatives
4.2 Industry Investments and Initiatives

5 Breast Cancer Liquid Biopsy Market

6 Breast Cancer Liquid Biopsy Market: Competitive Landscape

7 Appendix
7.1 Knowledge Store: Marketsandmarkets’ Subscription Portal
7.2 Introducing RT: Real-Time Market Intelligence
7.3 Available Customizations
7.4 Related Reports

Request for FREE Sample Report: To Know the Impact of COVID-19 on this Industry @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=15...

Views: 1

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service